What's new ? - 2017

What's new ? - 2017

Eli Lilly strategically reviewing Elanco Animal Health business

31 October, 2017

Eli Lilly & Co. said it could spin off or sell its animal health business, a segment that contributed 15% of the pharmaceutical company's revenue last year but has been pressured in recent years by competition.
Lilly's Elanco Animal Health Business sells treatments and vaccines for pets and livestock. The unit brought in $740.6 million of revenue in the third quarter, up 5% from a year ago. Overall the company's third-quarter revenue was $5.66 billion.
Revenue from livestock animal treatments decreased 6% in the latest quarter from a year ago, partly due to competitive pressures in the U.S. cattle industry. Revenue from companion animals such as dogs and cats increased 35%, mainly due to an acquisition of Boehringer Ingelheim Vetmedica's U.S. feline, canine and rabies vaccine portfolio and increases in wholesale purchases.